High Fidelity RNA Editor Development & Studies Supporting the World’s First CRISPR/RNA-Targeting Therapy, HG202, for Patients with Neovascular Age-Related Macular Degeneration
- Identification, protein engineering and characterization of high fidelity hfCas12Y
- The opportunity and advantages or RNA editing for Neovascular Age-Related Macular Degeneration (nAMD)
- The molecular composition, mechanism of action, and preclinical animal studies of RNA editor HG202